Your session is about to expire
Inside Her2 Negative Breast Cancer
HER2-Negative vs. Positive: Understanding Proteins, Diagnosis, and Prevalence in Cancer
HER2 refers to a protein that influences the growth of cancer cells. In some cancers, this protein is present in high amounts and leads to rapid disease progression. The designation of HER2-negative or HER2-positive is determined by the presence or absence of this protein on cancer cells.
The human epidermal growth factor receptor 2 (HER2) is a gene that produces HER2 proteins found on breast cells, which are involved in the regulation of cell growth, division, and repair in a healthy context. However, malfunctioning of the HER2 gene, leading to gene amplification, results in an overproduction of HER2 proteins (protein overexpression). This overproduction can cause breast cells to proliferate uncontrollably, potentially resulting in cancer.
The determination of a cancer's HER2 status is achieved through tests that examine the tumor tissue:
- Immunohistochemistry (IHC), which measures the amount of HER2 protein on the surfaces of cells.
- Fluorescence in situ hybridization (FISH), which identifies extra copies of the HER2 gene within cells. A positive result from these tests indicates an excess amount of HER2 protein or genes, while a negative result indicates normal levels.
The prevalence of HER2 positivity is not confined to a single type of cancer, though it is most commonly associated with breast cancer, where approximately 20% of cases are found to be HER2-positive. This condition also occurs in other types of cancer, such as ovarian and stomach cancers, albeit less frequently.
The identification of a cancer’s HER2 status is crucial for the determination of potential treatment options, as specific therapies targeting these proteins are available and beneficial primarily to those with a positive status.
Diagnostic Tests and Impact on Breast Cancer Staging for HER2 Status
[Breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) diagnosis often leads to a series of tests, including one critical test that determines the HER2 status. HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that can promote the growth of cancer cells. In approximately one in five breast cancers, the cancer cells produce an excess of the HER2 protein due to a gene mutation.
There are two main types of tests used to check for HER2: Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).
- IHC measures the amount of HER2 protein on the surface of cells in a breast cancer tissue sample. The results range from 0 to 3+, with scores of 0 or 1+ considered negative for overexpression and scores of 3+ considered positive, indicating an excess of HER2 protein.
- A score of 2+ is seen as borderline; this typically necessitates further testing with FISH, which examines the genes inside the cells.
The determination of HER2 status has significant implications for staging. Tumors that are ER-positive but also have high levels of HER2 might not respond as well to hormone therapy alone but may respond effectively to treatments targeting both ER and HER proteins. Additionally, certain medications specifically target these overexpressed HER2 receptors, which can shrink tumors or slow their growth.
The identification of HER2 status provides important information about the specific type of breast cancer and its behavior. This knowledge plays a critical role in making decisions around chemotherapy, targeted therapy, hormone therapy, and surgical options, affecting the overall management of the condition.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
Treatment and Advancements for HER2-Negative and -Positive Cancer
Cancer treatment has evolved with a focus on the specifics of a cancer type for selecting the most effective treatment. This is particularly true for breast cancer, categorized by hormone receptor status: HER2-negative or HER2-positive.
For HER2-positive cancer, treatments often include targeted therapies. These drugs are designed to attack specific parts of cancer cells. Trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein on the surface of cancer cells, helping to stop their growth. New advancements have led to more options like ado-trastuzumab emtansine (Kadcyla), a drug that combines Herceptin with a chemotherapy drug, directly targeting and killing cancer cells.
Treatment for HER2-negative breast cancers differs as these do not respond to therapies targeting the HER2 protein. Treatment may focus on hormone therapy if the cancer is hormone receptor-positive or chemotherapy if it's triple-negative (not responding to estrogen, progesterone, or HER2). Recently developed PARP inhibitors have shown promise in treating certain types of HER-negative breast cancers by blocking enzymes that help repair DNA damage in tumor cells.
Continuous research contributes to the development of better-targeted therapies and the advancement of personalized medicine approaches.
HER2-Low Breast Cancer Classification and Targeted Therapies
[Breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) encompasses various types, distinguished by the presence of specific receptors on cancer cells, which can influence both the choice of treatment and the prognosis. A notable classification within this spectrum is HER2-low breast cancer.
HER2, or Human Epidermal growth factor Receptor 2, plays a role in the proliferation of breast cancer cells. Traditionally, breast cancers were classified as either HER2-positive or HER2-negative, based on the abundance of this protein. Recent advancements, however, have led to the identification of an intermediate category known as HER2-low. This classification includes tumors with more HER2 expression than HER2-negative cases but insufficient levels to qualify as HER2-positive.
The identification of the HER2-low category has been pivotal in the development of targeted therapy options. These treatments are designed to attack specific characteristics of cancer cells. For HER2-low breast cancer, the creation of therapies that specifically cater to this intermediate level of HER2 expression has been a significant advancement.
Among the targeted therapies for HER2-low breast cancer is Trastuzumab deruxtecan. This innovative drug is designed for the treatment of HER2-low breast cancer, combining trastuzumab—an agent that binds to the HER2 receptor on tumor cells—with a chemotherapy drug that is delivered directly to these cells.
The benefits of such targeted therapies include:
- Enhanced precision in targeting tumor cells
- Minimized effects on healthy tissues
- The potential for improved survival rates and quality of life
The advent of therapies specifically for HER2-low breast cancer marks a significant development in the treatment of this disease, providing a more nuanced approach to care. The categorization into HER2-low has refined treatment strategies, enabling more personalized care for individuals facing this complex condition.